PHASE 3 RANDOMIZED TRIAL OF MOMELOTINIB VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH MYELOFIBROSIS PREVIOUSLY TREATED WITH RUXOLITINIB: RESULTS OF THE SIMPLIFY-2 STUDY

被引：0
|
作者：
Verstovsek, S. [1 ]
Vannucchi, A. M. [2 ]
Platzbecker, U. [3 ]
Cervantes, F. [4 ]
Gupta, V. [5 ]
Lavie, D. [6 ]
Passamonti, F. [7 ]
Winton, E. F. [8 ]
Dong, H. [9 ]
Kawashima, J. [9 ]
Maltzman, J. D. [9 ]
Kiladjian, J-J. [10 ,11 ]
Harrison, C. N. [12 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Florence, Florence, Italy
[3] Tech Univ, Med Fak Carl Gustav Carus, Dresden, Germany
[4] Univ Barcelona, Hosp Clin, Barcelona, Spain
[5] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada
[6] Hadassah Hebrew Univ Med Ctr, Jerusalem, Israel
[7] Univ Insubria, Varese, Italy
[8] Emory Univ, Sch Med, Atlanta, GA USA
[9] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA
[10] St Louis Hosp, AP HP, Paris, France
[11] Paris Diderot Univ, Paris, France
[12] Guys & St Thomas NHS Fdn Trust, London, England
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S786
引用
收藏
页码：320 / 321
页数：2
相关论文
共 50 条
  • [31] A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: stage 2 of a phase II trial
    Verstovsek, Srdan
    Talpaz, Moshe
    Wadleigh, Martha
    Isidori, Alessandro
    te Boekhorst, Peter
    Savona, Michael R.
    Bose, Prithviraj
    Pozdnyakova, Olga
    Mesa, Ruben
    El-Galaly, Tarec C.
    O'Sullivan, Jennifer
    Gamel, Katia
    Higgins, Brian
    Katakam, Sudhakar
    Todorov, Boyan
    Trunzer, Kerstin
    Harrison, Claire N.
    HAEMATOLOGICA, 2024, 109 (06) : 1977 - 1983
  • [32] The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: An open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis
    McMullin M.F.
    Harrison C.N.
    Niederwieser D.
    Demuynck H.
    Jäkel N.
    Gopalakrishna P.
    McQuitty M.
    Stalbovskaya V.
    Recher C.
    Theunissen K.
    Gisslinger H.
    Kiladjian J.-J.
    Al-Ali H.-K.
    Experimental Hematology & Oncology, 4 (1)
  • [33] Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis
    Hans Michael Kvasnicka
    Jürgen Thiele
    Carlos E. Bueso-Ramos
    William Sun
    Jorge Cortes
    Hagop M. Kantarjian
    Srdan Verstovsek
    Journal of Hematology & Oncology, 11
  • [34] Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis
    Kvasnicka, Hans Michael
    Thiele, Juergen
    Bueso-Ramos, Carlos E.
    Sun, William
    Cortes, Jorge
    Kantarjian, Hagop M.
    Verstovsek, Srdan
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
  • [35] Phase 3 trial of momelotinib (MMB) vs ruxolitinib (RUX) in JAK inhibitor (JAKi) naive patients with myelofibrosis (MF).
    Mesa, Ruben A.
    Kiladjian, Jean -Jacques
    Catalano, John V.
    Devos, Timothy
    Egyed, Miklos
    Hellman, Andrzei
    McLornan, Donal
    Shimoda, Kazuya
    Winton, Elliott F.
    Deng, Wei
    Dubowy, Ronald L.
    Maltzman, Julia D.
    Cervantes, Francisco
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [36] CHANGES IN BONE MARROW MORPHOLOGY IN PATIENTS WITH MYELOFIBROSIS TREATED FOR UP TO 5 YEARS WITH EITHER RUXOLITINIB OR BEST AVAILABLE THERAPY
    Kvasnicka, H. M.
    Thiele, J.
    Bueso-Ramos, C. E.
    Sun, W.
    Cortes, J.
    Kantarjian, H. M.
    Verstovsek, S.
    HAEMATOLOGICA, 2014, 99 : 127 - 128
  • [37] LONG-TERM INTERVENTION EFFECTS ON BONE MARROW MORPHOLOGY IN MYELOFIBROSIS: PATIENTS TREATED WITH RUXOLITINIB AND BEST AVAILABLE THERAPY
    Kvasnicka, H.
    Thiele, J.
    Bueso-Ramos, C. E.
    Sung, W.
    Cortes, J.
    Kantarjian, H. M.
    Verstovsek, S.
    HAEMATOLOGICA, 2013, 98 : 249 - 249
  • [38] Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
    C N Harrison
    A M Vannucchi
    J-J Kiladjian
    H K Al-Ali
    H Gisslinger
    L Knoops
    F Cervantes
    M M Jones
    K Sun
    M McQuitty
    V Stalbovskaya
    P Gopalakrishna
    T Barbui
    Leukemia, 2016, 30 : 1701 - 1707
  • [39] Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
    Harrison, C. N.
    Vannucchi, A. M.
    Kiladjian, J-J
    Al-Ali, H. K.
    Gisslinger, H.
    Knoops, L.
    Cervantes, F.
    Jones, M. M.
    Sun, K.
    McQuitty, M.
    Stalbovskaya, V.
    Gopalakrishna, P.
    Barbui, T.
    LEUKEMIA, 2016, 30 (08) : 1701 - 1707
  • [40] Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib (vol 79, pg 38, 2019)
    Gerds, Aaron T.
    Tauchi, Tetsuzo
    Ritchie, Ellen
    Deininger, Michael
    Jamieson, Catriona
    Mesa, Ruben
    Heaney, Mark
    Komatsu, Norio
    Minami, Hironobu
    Su, Yun
    Shaik, Naveed
    Zhang, Xiaoxi
    DiRienzo, Christine
    Zeremski, Mirjana
    Chan, Geoffrey
    Talpaz, Moshe
    LEUKEMIA RESEARCH, 2019, 81 : 105 - 105
12345